Share this: FacebooktwittermailFacebooktwittermail

Gilead announced its committed to ensuring that people at risk of HIV have access to Truvada for PrEP (emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg) tablets. Gilead supports comprehensive payer coverage and maintains the Gilead Advancing Access program for qualified underinsured and uninsured people in the U.S. who cannot afford their medications. This includes the Truvada for PrEP co-pay assistance program for commercially insured individuals, and the compnay’s Medication Assistance Program (MAP), which provides free medication for those who qualify based on financial need.

As insurance plans change, out-of-pocket costs for some individuals may have increased. To address the affordability challenges, Gilead regularly evaluates its support programs for people at risk of HIV who are either considering or taking Truvada for PrEP.

Gilead announced two significant changes to its Advancing Access program:

  • Effective September 1, 2018, Gilead will increase its annual benefit for Truvada from up to $4,800 to $7,200. This increase will apply to both Truvada for PrEP and Truvada for chronic HIV treatment as part of a complete three-drug regimen. Enrollment terms and conditions will remain the same. Gilead’s co-pay coupon program is not available for patients enrolled in any state or federally funded prescription drug program, such as Medicare Part D and Medicaid.
  • Effective July 1, 2018, people who qualify for Gilead’s MAP will be eligible for 12 months rather than six months. This change will make it easier for people to enroll and remain in the program.

Since 2014, a total of 146,329 unique individuals have received support through the co-pay assistance program. So far this year, 15,264 unique individuals have received free drug through the Truvada for PrEP MAP.

Anyone facing affordability challenges in accessing Truvada for PrEP can contact Gilead at